THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to include ...
Repatha VESALIUS-CV Trial Met Dual Primary Endpoints Demonstrating Reduction in CV Events in High-Risk Patients Who Have Never Had a Heart Attack or Stroke Real-World Evidence from the Repatha-CE ...
(RTTNews) - Amgen (AMGN) announced detailed findings from its Phase 3 VESALIUS-CV clinical trial, revealing that Repatha (evolocumab) significantly reduces major adverse cardiovascular events (MACE) ...
DEAR DR. ROACH: I am a 52-year-old woman who was diagnosed with familial hypercholesterolemia in October 2024. I went through a cardiac workup for pain in my left arm and found this out. My ...
Target RWE, a leader in advancing modern evidence generation for complex clinical and regulatory challenges, today announced the presentation of compelling new findings from the REPATHA-CE study of ...
LOS ANGELES (Reuters) -Amgen on Monday launched direct-to-consumer U.S. sales of its cholesterol medication Repatha at a discounted cash price, becoming the latest pharmaceutical company responding to ...
LOS ANGELES (Reuters) -Amgen on Monday launched direct-to-consumer U.S. sales of its cholesterol-lowering medication Repatha at a discounted cash price, becoming the latest pharmaceutical company to ...
Amgen AMGN announced the launch of a new direct-to-consumer (DTC) program called AmgenNow, which will offer significant discounts on its marketed drugs. The company has initiated this DTC program with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results